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Abstract
Background: Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by deficiency in
acid beta-glucosidase. GD exhibits a wide clinical spectrum of disease severity with an unpredictable natural course.
Plasma chitotriosidase activity and CC chemokine ligand 18 (CCL18) have been exchangeably used for monitoring
GD activity and response to enzyme replacement therapy in conjunction with clinical assessment. Yet, a large-scale
head-to-head comparison of these two biomarkers is currently lacking. We propose a collaborative systematic
review with meta-analysis of individual participant data (IPD) to compare the accuracy of plasma chitotriosidase
activity and CCL18 in assessing type I (i.e., non-neuropathic) GD severity.
Methods: Eligible studies include cross-sectional, cohort, and randomized controlled studies recording both plasma
chitotriosidase activity and CCL18 level at baseline and/or at follow-up in consecutive children or adult patients
with type I GD. Pre-specified surrogate outcomes reflecting GD activity include liver and spleen volume,
hemoglobin concentration, platelet count, and symptomatic bone events with imaging confirmation. Primary
studies will be identified by searching Medline (1995 onwards), EMBASE (1995 onwards), and Cochrane Central
Register of Controlled Trials (CENTRAL). Electronic search will be complemented by contacting research groups in
order to identify unpublished relevant studies. Where possible, IPD will be extracted from published articles.
Corresponding authors will be invited to collaborate by supplying IPD. The methodological quality of retrieved
studies will be appraised for each study outcome, using a checklist adapted from the Quality Assessment of
Diagnostic Accuracy Studies-2 tool. The primary outcome will be a composite of liver volume >1.25 multiple of
normal (MN), spleen volume >5 MN, hemoglobin concentration <11 g/dL, or platelet count <100 × 109/L. Effect size
estimates for biomarker comparative accuracy in predicting outcomes will be reported as differences in areas under
receiver operating characteristic curves along with 95% confidence intervals. Effect size estimates will be reported
as (weighted) mean differences along with 95% confidence intervals for each biomarker according to outcomes.
IPD meta-analysis will be conducted with both one- and two-stage approaches.
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Discussion: Valid and precise accuracy estimates will be derived for CCL18 relative to plasma chitotriosidase activity
in discriminating patients according to GD severity.
Systematic review registration: PROSPERO 2015 CRD42015027243
Keywords: Gaucher disease, Biomarkers, Chemokines, CC, Hexosaminidases, Hepatomegaly, Splenomegaly, Anemia,
Thrombocytopenia, Humans
Background
Gaucher disease (GD) is the most frequent recessively
inherited lysosomal storage disorder, with an estimated
prevalence of one in 40,000 to 60,000 individuals in the
general population [1]. GD is caused by the accumulation
of glucosylceramide (glucocerebroside) in tissue macro-
phages resulting from deficiency in lysosomal acid beta-
glucosidase (glucocerebrosidase) activity [2]. Gaucher cells
(i.e., glucocerebroside-laden macrophages) displace and/or
affect normal cells in bone marrow and visceral organs,
causing anemia, thrombopenia, hepatosplenomegaly,
skeletal manifestations, and organ dysfunctions [3].
The clinical spectrum of GD ranges from lethal disease
during infancy to symptom onset in late adulthood [4].
Although early onset of GD in childhood generally pre-
dicts rapidly progressive form, the natural course of the
disease is rather unpredictable [4]. Additionally, GD may
progress at different rates in different organs and disease
severity in one organ may not relate to disease in other
organs [4]. Type I GD, which accounts for 90% of all
patients with GD in Western countries, is characterized
by the absence of early neurological manifestation onset
in contrast to the much less frequent acute (type II) and
chronic (type III) neuronopathic variants [5].
Since 1991, enzyme replacement therapy has been the
standard of care for patients with severe GD [6–8]. Sub-
strate reduction therapy has also proved to be safe and
effective in reducing hepatosplenomegaly and improving
hematological parameters [7, 8]. Quantitative measure-
ment of surrogate biochemical markers may be useful
for assisting clinicians in their decision making for the
initiation or adjustment of enzyme replacement or sub-
strate reduction therapy, in patients with GD [9].
Current guidelines recommend measuring plasma
chitotriosidase activity for monitoring GD in conjunc-
tion with clinical assessments [9]. Chitotriosidase, a
human analog from non-vertebrate chitinase, is specific-
ally expressed by chronically activated phagocytes and
released by glucocerebroside-laden macrophages [10].
Plasma chitotriosidase activity is elevated 1000-fold
above normal values in patients with active GD and has
been suggested to indicate total body Gaucher cell load
[11]. Plasma chitotriosidase activity level correlates with
liver and spleen volume, hemoglobin concentration,
platelet count, and bone manifestations [12]. Plasma
chitotriosidase activity decreases dramatically after
initiation of enzyme replacement therapy and rises when
treatment is stopped [13].
Yet monitoring plasma chitotriosidase activity has
limitations. First, analysis of plasma chitotriosidase activ-
ity is technically complex and not standardized across
laboratories [14], rendering its interpretation tricky [15].
Second, 6% of the population are homozygous for a chit-
otriosidase variant, due to a 24-base pair duplication in
the chitotriosidase gene, and are deficient in chitotriosi-
dase activity [16]. Third, 35% of the population are
heterozygous for this null chitotriosidase variant and
express approximately half the activity observed in those
who are wild type [15]. Fourth, other polymorphisms
have been reported, leading to slightly impaired enzyme
activity compared with wild type [10].
CC chemokine ligand 18 (CCL18), originally named
pulmonary and activation-regulated chemokine (PARC),
is a CC chemokine produced by macrophages in re-
sponse to “alternative activation” [15]. Plasma CCL18
level is elevated 10- to 50-fold above normal values in
patients with active GD. Plasma CCL18 originates from
Gaucher cells disseminated in various body locations
and reflects the overall body burden of Gaucher cells
[17]. CCL18 level correlates with liver and spleen
volume, platelet count, history of osteonecrosis, and
number of anatomical sites of osteonecrosis [15, 18].
Despite a strong correlation between the two biomarkers
[15], CCL18 has theoretically potential advantages over
chitotriosidase for monitoring GD activity. First,
enzyme-linked immunosorbent assay (ELISA) of CCL18
is amenable to standardization across laboratories [15].
Second, CCL18 is suitable for measuring GD activity in
patients who are deficient in chitotriosidase activity [17].
Third, CCL18 levels tend to reflect more closely spleen
volume and platelet count during treatment than does
chitotriosidase activity [15].
Although chitotriosidase activity and CCL18 are
considered equivalent in routine practice, a large-scale,
head-to-head comparison of their performance in asses-
sing GD severity is currently lacking. We hypothesize
that research evidence on the comparative accuracy for
these two biomarkers can be strengthened by secondary
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analysis of individual participant data (IPD) from
primary studies.
Aims and objectives
The aim of this systematic review with meta-analysis of
IPD is to compare the accuracy of plasma chitotriosidase
activity and CCL18 level for assessing type I GD activity.
The primary hypothesis guiding this project is that both
plasma chitotriosidase activity and CCL18 level relate to
visceral, hematological, and skeletal disease activity in
GD patients. The secondary hypothesis is that the accur-
acy of chitotriosidase activity and CCL18 may differ in
discriminating GD patients according to disease severity.
The primary objective is to compare the accuracy of
CCL18 relative to chitotriosidase activity in discriminating
patients with a composite of hepatomegaly, splenomegaly,
anemia, or thrombocytopenia. The secondary objective is
to compare the accuracy of CCL18 relative to chitotriosi-
dase activity for discriminating patients with symptomatic
bone events with imaging confirmation.
Methods
Study design
This systematic review with meta-analysis of IPD will be
conducted according to current guidelines [19, 20]. The
present protocol complies with the Preferred Reporting
Items for Systematic review and Meta-Analysis
(PRISMA)-Protocol 2015 statement [21]. It describes
how primary studies will be identified, data collection
will be undertaken, IPD will be analyzed and findings
will be interpreted.
Eligibility criteria
Study designs
Eligible studies include cross-sectional and cohort stud-
ies measuring both plasma chitotriosidase activity and
serum CCL18 level at baseline and/or at follow-up.
Because randomized controlled trials evaluating enzyme
replacement or substrate reduction therapy are a special
case of prospective cohort studies [22], they will be also
considered for inclusion. Yet, diagnostic accuracy or
retrospective case-control studies evaluating the per-
formance of chitotriosidase activity and/or CCL18 level
in discriminating patients with GD and healthy control
subjects, as well as case reports are not within the scope
of this review.
Participants
Primary studies enrolling consecutive children or adult
patients with objective confirmation of GD will be in-
cluded. We will focus on non-neuronopathic (i.e., type I)
GD because this is the most prevalent phenotype with
visceral manifestations being improved by enzyme
replacement therapy. Naïve participants (i.e., without a
history of treatment) as well as those receiving symp-
tomatic treatment or undergoing enzyme replacement
or substrate reduction therapy will be considered for
inclusion. Deficiency in chitotriosidase activity will not
be an exclusion criterion. Studies enrolling less than 10
participants will be excluded from the review.
Index test
Relevant methods for quantitative measurement of
serum CCL18 level include enzyme-linked immunosorb-
ent assay (ELISA) [17] and dissociation-enhanced
lanthanide fluoroimmunoassay (DELFIA) [23].
Comparator
The comparator is quantitative measurement of plasma
chitiotriosidase activity with the use of fluorogenic substrate
molecules, including 4-methyllumbelliferyl-chitobiose, 4-
methyllumbelliferyl-chitotriose, or 4-methyllumbelliferyl-
deoxy-chitotrioside [11, 14, 24].
Outcomes
Pre-specified surrogates reflecting disease severity in-
clude anemia, thrombocytopenia, splenomegaly, hepato-
megaly, and symptomatic bone events with imaging
confirmation [25].
Timing and setting
Studies with baseline and/or follow-up data for CCL18
level, chitotriosidase activity, and one or more pre-
specified outcomes will be included. Because patients
were enrolled at varying time from disease onset across
studies, we will collect the age at GD diagnosis and at
evaluation. We anticipate that the length of follow-up
ranges between 6 and 12 months for most randomized
controlled trials. However, longer follow-up times are
expected for patients enrolled in observational prospect-
ive cohort studies, study extensions, or ongoing regis-
tries. There will be no restrictions by type of setting.
Language
Electronic literature searches will be conducted without
language restrictions. However, full-text articles
published in languages other than English, Russian, or
French will not be assessed for eligibility because of lim-
ited resources for translation. For transparency purpose,
we will provide a list of potentially relevant articles
published in other languages in an appendix.
Information sources
Electronic databases
Studies will be identified by searching Medline via
PubMed (1995 onwards), EMBASE via Ovid (1995 on-
wards), and Cochrane Central Register of Controlled
Trials (CENTRAL) via Wiley interface (current issue).
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The first report on increased plasma chitotriosidase ac-
tivity in patients with GD was published in 1994 [11].
The first paper reporting on increased chemokine
CCL18/PARC level in Gaucher disease was published by
the same research group, 10 years later [17]. Because a
direct comparison of the accuracy for these two
biomarkers was unlikely to be published before this date,
our searches have been restricted to 1995 onwards. Our
preliminary searches did not identify any relevant
citation prior to 2004.
Other information sources
We will supplement the electronic search by scanning
the reference lists of retrieved original articles and previ-
ously published review articles for additional studies. We
will search clinicaltrials.gov and the WHO international
clinical trials registry platform in order to identify
enzyme replacement and/or substrate reduction therapy
trials that routinely evaluated chitotriosidase activity and
CCL18 as surrogate biochemical markers of GD activity.
Additionally, we will contact research groups, authors of
relevant articles, and prominent clinicians within the
field in order to identify ongoing or completed but not
yet published relevant studies.
Search strategy
Electronic search strategies will be developed by a mem-
ber from the coordinating group and critically reviewed
by a health sciences librarian, using the Peer Review of
Electronic Search Strategies (PRESS)-2015 Guideline
Statement [26]. The search concepts will include plasma
chitotriosidase activity, CCL18, biological markers,
enzyme replacement therapy, and Gaucher disease. We
will use both standardized medical subject heading
(MeSH) and text words (Additional file 1: Appendix 1).
No type of document restrictions will be applied and no
methodology filters will be used. After the Medline
search strategy is finalized, adjustments will be made to
account for differences in syntax and subject headings
(EMTREE) across electronic bibliographic databases. A
member from the coordinating group with experience of
searching for systematic reviews will execute electronic
searches.
Study records
Data management
Literature search results will be uploaded along with
titles and abstracts into a reference management soft-
ware. We will attempt to identify duplicate publications
reporting data from the same study by comparing author
names, study sites, and sample sizes. Ultimately, corre-
sponding authors will be contacted to obtain clarifica-
tion on potential overlapping or inconsistencies across
multiple reports of the same study.
Selection process
Two review authors will independently screen citation
titles and abstracts, where available, yielded by the litera-
ture search against pre-specified eligibility criteria. The
screening process will assess whether the citation (1)
reported data from an original research study, (2) fo-
cused on patients with GD, (3) evaluated plasma chito-
triosidase activity, (4) evaluated serum CCL18 level, and
(5) captured one or more pre-specified outcomes of
interest. The two review authors will rate each citation
using a “relevant,” “irrelevant,” “unsure” (whether rele-
vant or irrelevant) designation. Full-text articles will be
retrieved for citations that received a “relevant” or “un-
sure” classification from at least one of the two review
authors. Records rated “irrelevant” by the two review
authors will be discarded for further review.
Two review authors will independently assess full-text
articles and decide if they meet pre-specified eligibility
criteria, using a standardized eligibility form (Additional
file 2: Appendix 2). We will contact corresponding
authors to obtain additional information about study
eligibility, where necessary. Disagreements will be re-
solved by discussion between the two review authors.
Reasons for excluding study records will be recorded.
Data collection
Two review authors will independently perform qualita-
tive and quantitative data extraction. For this purpose, a
data extraction form will be developed, pretested, and
adjusted as necessary. Disagreements will be resolved by
discussion between the two review authors.
Where possible, IPD will be extracted from published
articles and entered into a database. A hematologist with
expertise in GD research and clinical management will
invite corresponding authors and/or principal investiga-
tors of eligible primary studies to collaborate in this sys-
tematic review project by providing us with IPD. Each
corresponding author and/or principal investigator will
be first approached during international conferences or
contacted by both regular and electronic mails. Contact
information will be retrieved from published articles and
online search. A reminder will be e-mailed to non-
respondents 1 month later. A co-author of the primary
study will be contacted in case of non-response from
both the principal investigator and corresponding
author. Pharmaceutical companies that funded clinical
trials of enzyme replacement or substrate reduction
therapy will be also contacted.
Correspondence will enclose a cover letter, the system-
atic review protocol, the list of requested variables, and a
consent form for participating in the systematic review
[27]. The cover letter will emphasize the collaborative
nature of the project, ensure that supplied data will be
held securely and treated as confidential, and offer
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participants the opportunity for co-authoring the final
report.
If they agree to participate, investigators will be asked
for providing de-identified individual data for all patients
enrolled in studies. Ultimately, investigators unable to
provide IPD will be invited to provide us with aggregate
data in tabular formats for pre-specified analyses. Inves-
tigators who decline to provide IPD will be surveyed for
identifying potential reasons for not participating in the
project.
Data checking
For each primary study, the data will be cross-checked
with respect to range, missing values, and consistency
with published reports. Attempts will be made to resolve
inconsistencies by discussion with primary study investi-
gators. If required, converted data will be sent to the in-
vestigators for verification. Because the relationship
between the biomarkers under review (i.e., plasma chito-
triosidase activity and CCL18) and the pre-specified out-
comes is observational in nature, we will not assess
randomization integrity nor selective outcome reporting
for randomized controlled trials of enzyme replacement
or substrate reduction therapy. We anticipate that
patients who are deficient for chitotriosidase activity at
baseline will not be tested for this biomarker at follow-
up visits.
Raw data from all primary studies will be collated into
a single meta-analysis database, including a primary
study identifier. Where possible, participants enrolled in
several primary and/or extension studies will be assigned
a unique identifier. All primary study raw datasets and
meta-analysis databases will be stored in a password-
protected area of a secure server. Access to databases
will be limited to staff working directly on the project.
No data will be used for any other purpose without
permission of all collaborators.
Data items
Details of study- and participant-level characteristics will
be extracted from reports of primary published articles
at this stage. Requested IPD items include variables col-
lected at baseline and at each follow-up visit (Table 1).
Studies with insufficient data on a pre-specified outcome
despite contacting the authors will be excluded from the
IPD meta-analysis for this outcome only.
Outcomes
The pre-specified outcomes are derived from liver vol-
ume, spleen volume, hemoglobin concentration, platelet
count, and symptomatic bone events with imaging
confirmation (Table 2). The primary outcome is a com-
posite of hepatomegaly, splenomegaly, anemia, and
thrombocytopenia. The secondary outcomes include
symptomatic bone manifestations with imaging confirm-
ation, a composite of massive hepatomegaly or spleno-
megaly, severe anemia or thrombocytopenia, and
individual components of the primary and secondary
composite outcomes. Cut-off values for continuous
parameter are set according to published guidelines or
previous studies [28, 29].
We anticipate that organ volumetric data will be
derived by computed tomography, magnetic resonance,
or ultrasound imaging, depending on the technology
available. Organ volumes will be expressed as multiples
Table 1 Requested variables
Variable Description
Gender Male, female
Age at baseline Year
Age at GD diagnosis Year
Site of enrollment Country
Acid beta-glucosidase genotype –
Chitotriosidase genotype Deficient[homozygous];
heterozygous; wild type
Previous history of enzyme
replacement therapy at
enrollment
Never treated with ERT, no ERT
within the previous year, ERT
within the previous year
Previous history of substrate
reduction therapy at enrollment
Never treated with SRT, no SRT
within the previous year, SRT
within the previous year
Splenectomy Yes, no
Time to FU visit Month (0 for baseline)
Treatment received at FU Placebo, untreated, imiglucerase,
velaglucerase alpha, taliglucerase,
miglustat, eliglustat, other
Plasma chitotriosidase activity
at FU
nmol/mL/h
Serum CCL18 level at FU ng/mL
Hemoglobin concentration at FU g/dL
Platelet count at FU 109/L
White blood cell count at FU 109/L
Liver volume at FU MN
Spleen volume at FU MN
Previous history of bone event Yes, no
Osteonecrosis (i.e., clinical history
of bone crises with radiologic or
magnetic resonance imaging
confirmation) within the previous
12 months
Yes, no
Fracture with imaging
confirmation within the previous
12 months
Yes, no
Skeletal site of fracture Spine, hip, femur, knee, distal to the
knee, shoulder, clavicle, humerus,
elbow, distal to the elbow, rib, other
Abbreviations: GD Gaucher disease, ERT enzyme replacement therapy, FU
follow-up; MN multiple of normal, SRT substrate reduction therapy
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of normal (MN) adjusted for body weight. The normal
spleen volume will be computed as 2 mL/kg multiplied
by weight in kilograms in patient who did not undergo
any splenectomy procedure. The normal liver volume
will be computed as 25 mL/kg multiplied by weight in
kilograms.
Assessment of methodological quality
Two review authors will independently appraise the meth-
odological quality of included studies for each outcome of
interest, using a checklist adapted from the Quality Assess-
ment of Diagnostic Accuracy Studies (QUADAS)-2 tool
[30]. The QUADAS-2 tool comprises four domains in-
cluding patient selection, index test, reference standard,
and flow and timing. Each domain is evaluated in terms of
risk of bias while the first three domains are also assessed
with respect to applicability to clinical practice [30].
Disagreement in risk of bias and/or applicability between
the two review authors will be resolved by discussion.
Data synthesis
A statistical analysis plan will be developed by the pro-
ject statistician with complete details and definitions of
all planned analyses. This statistical analysis plan will be
reviewed by the study chairman and an independent
statistician prior to database lock.
Analytical sample
A PRISMA-style flow diagram [31] will illustrate the
process of primary study selection from identification to
inclusion in the meta-analysis. No primary study will be
excluded from meta-analysis based on methodological
quality assessment results. Primary studies that did not
gather data for a pre-specified outcome will not be
included in the meta-analysis for this outcome only.
Study characteristics
Information on key primary study and participant char-
acteristics, chitotriosidase activity and CCL18 assays,
and study methodological quality will be summarized in
separate tables.
Effect size estimates
Effect size estimates for biomarker comparative accuracy
in predicting outcomes will be reported as differences in
areas under receiver operating characteristic (ROC)
curves along with 95% confidence intervals. Effect size
estimates will be reported as (weighted) mean differ-
ences along with standard errors and/or 95% confidence
intervals, where appropriate. For highly skewed distribu-
tions, we will compute (weighted) mean differences
(along with standard error) after logarithm transform-
ation and then derived ratios of geometric means along
with 95% confidence intervals [32].
Data synthesis
As recommended [33], meta-analysis of IPD will be con-
ducted with both two- and one-stage approaches. In
two-stage approach, the first stage implies analyzing IPD
within primary studies in order to generate study-level
effect size point estimates and variances. In the second
stage, point estimates from each primary study are com-
bined using conventional meta-analytical methods. Be-
cause aggregate data on the comparative accuracy of
chitotriosidase activity and CCL18 in predicting pre-
specified outcomes were not reported in most published
articles, we anticipate that combination of aggregate data
with IPD will not be feasible. This two-stage approach
provides summary effect size point estimates along
with 95% confidence intervals, which account for
between-study heterogeneity. Basically, we will use a
DerSimonian and Laird’s random-effects meta-analysis
model for combining weighted mean differences in
plasma chitotriosidase activity and CCL18 levels (after
logarithm transformation, if necessary) for patients
with and without each pre-specified outcome [34].
Difference in areas under the ROC curve estimates
will be pooled using random-effects meta-analysis
models for plasma chitotriosidase activity and serum
CCL18 level [35].
Table 2 Pre-specified surrogate outcomes reflecting Gaucher
disease activity
Outcomes Definitiona
Primary outcome The primary outcome is a composite of one
or more individual components among
the following:
- Liver volume >1.25 MN
- Spleen volume >5 MN
- Hemoglobin concentration <11.0 g/dL
(<10.0 g/dL for patients 6 to 59 months of age)
- Platelet count <100 × 109/mL
Secondary outcomes 1. Composite of one or more individual
components among the following:
- Liver volume >2.5 MN
- Spleen volume >15 MN
- Hemoglobin concentration <8.0 g/dL
(<7.0 g/dL for patients 6 to 59 months of age)
- Platelet count <50 × 109/mL
2. Symptomatic bone manifestations with
imaging confirmation including the following:
- Osteonecrosis
- Fracture
Abbreviation: MN multiple of normal
aOrgan volumes will be expressed as multiples of normal (MN) adjusted for
body weight. The normal spleen volume will be computed as 2 mL/kg
multiplied by weight in kilograms in patient who did not undergo any
splenectomy procedure. The normal liver volume will be computed as 25 mL/
kg multiplied by weight in kilograms (see the “Methods” section)
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One-stage approach synthesizes individual patient data
in a single step, using a multilevel mixed-effects regres-
sion modeling that accounts for patient clustering within
primary studies. This approach allows incorporation of
patient-level covariates and exploration of potential in-
teractions involving patient- or study-level covariates.
Basically, we will fit three-level model for continuous
dependent variables (i.e., plasma chitotriosidase activity
or serum CCL18 level), with the three levels being
defined by observation, patient, and study [36, 37]. Each
pre-specified outcome will be entered as a binary
independent variable.
Estimates and paired-comparisons of areas under ROC
curves will be derived from nonparametric ROC regres-
sion models with bootstrap resampling, which accounts
for observation clustering within patients and primary
studies [38]. To quantify the incremental value of a dual
(i.e., a combination of chitotriosidase activity and
CCL18) in comparison with a single (i.e., either chito-
triosidase activity or CCL18) biomarker strategy, we will
compare areas under ROC curves derived from 3-level
logistic regression models. No indirect comparisons will
be performed.
Missing values
We anticipate missing values for biomarkers (i.e., plasma
chitotriosidase activity and CCL18) and outcomes of
interest (liver volume, spleen volume (for unsplenecto-
mized participants), hemoglobin level, and platelet
count). For transparency purpose, the completeness of
IPD will be reported for each variable separately and
overall for observations, within each primary study.
Complete case analysis, which discards all observations
with any missing value, will be undertaken in main ana-
lysis for each pre-specified outcome. To assess the
robustness of our findings, multiple imputation will be
used for replacing missing values. Missing values will be
imputed within primary studies in two-stage approach.
Investigation of heterogeneity
Between-study heterogeneity will be evaluated graphic-
ally by examining forest plots and statistically by using
the I2 inconsistency index [39]. The I2 index provides an
estimate of the percentage of total variance across stud-
ies due to heterogeneity rather than chance. A I2 index
of 0% indicates no evidence of heterogeneity, and larger
values reflect increasing heterogeneity [39].
Subgroup analyses
The following patient- and study-level covariates will be
entered in turn into one-stage approach model to exam-
ine the sources of heterogeneity in summary estimates:
age category (i.e., pediatrics versus adult patient),
enzyme replacement therapy within the previous year,
and fulfillment of QUADAS-2 criteria [30].
Sensitivity analysis
To assess the robustness of our findings, we will conduct
sensitivity analysis leaving out one primary study at a
time. Additional sensitivity analysis will be performed by
(1) substituting splenomegaly to splenectomy for the
primary and secondary composite outcomes and (2)
excluding patients who are deficient for chitotriosidase
activity (i.e., homozygotes).
Software
Most data manipulation, figures, and analyses will be
documented in Stata programs and performed using
Stata 14.0 Special Edition (Stata corp, College Station,
TX, USA). Multilevel mixed-effects regression will be
developed using Stata’s mixed and melogit commands.
Other data preparation and analyses will be performed
using Review Manager 5 (Cochrane Collaboration).
Reporting bias
For each outcome of interest reported by 10 or more
studies, evidence of publication bias will be assessed
graphically by examining a scatterplot of the effect size
estimates from primary studies against the standard
error [40]. A symmetrical funnel shape would be consist-
ent with the absence of selective reporting. Asymmetry
will be formally evaluated for statistical significance by
using Egger’s test [40].
Quality of evidence
We will assess the quality of evidence for summary
estimates using the Grading of Recommendations As-
sessment, Development and Evaluation (GRADE) rating
system based on six factors: study design, limitations
(i.e., risk of bias), indirectness of evidence, inconsistency
in results across studies, imprecision in summary
estimates, and likelihood of publication bias [41].
Protocol amendments
During the conduct of the meta-analysis, no protocol
changes will be made unless new information strongly
suggests that such changes would strengthen the scien-
tific validity of the findings. Suggested protocol changes
may originate from the primary study investigators who
participate in the review. If substantive modifications are
necessary that may impact on the review conduct or
results, including changes of study objectives, data ex-
traction methods, variable definitions, or significant ad-
ministrative aspects, they will require a formal
amendment to the protocol. Overall, the date, descrip-
tion of changes, and rationale for amendments will be
reported in a tabular format. The study chairman will
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ultimately be responsible for approving, documenting,
and implementing amendments.
Committees
Coordinating group
The systematic review coordinating group (TR, JL, MB)
is responsible for contacting and liaising with primary
study authors, data extraction, checking and analyses, in-
terpretation of findings, and preparing manuscripts for
publication.
IPD meta-analysis collaborative group
The IPD meta-analysis collaborative group will include
the members of coordinating group and a representative
from each primary study that provided individual par-
ticipant data. Clinicians with field expertise may be in-
vited to join the IPD meta-analysis collaborative group.
Updated lists of the IPD meta-analysis collaborative
group members will be available on the Prospective
Registry of Systematic Reviews (PROSPERO) website
throughout the conduct of the study. The IPD meta-
analysis collaborative group members will be consulted
at key stages of the project and given the opportunity to
be involved in data analysis, interpretation of the find-
ings, and critical review of the final manuscript.
Dissemination policy
Efforts will be made to reduce the interval between data
extraction completion and the release of the systematic
review and meta-analysis results. The members of the
coordinating systematic review group will prepare a
manuscript reporting the findings from the meta-
analysis in accordance with the 2015 PRISMA-IPD state-
ment [31]. The manuscript draft will be circulated for
approval by the members of the IPD meta-analysis
collaborative group before submission. The anticipated
date of completion is March 2018.
Discussion
Given the prevalence of GD in the general population
[5], most published studies that estimated the accuracy
of plasma chitotriosidase activity and CCL18 in predict-
ing disease activity are of relatively limited sample size.
A valid and reliable head-to-head comparison of these
two biomarkers would require a large sample size that
can only be supplied by an international prospective
study. Yet, such a study is unlikely to be designed due to
vested interests, local practices, and scarce resources.
In this context, our meta-analysis provides a unique
opportunity to compare the accuracy of CCL18 relative
to chitotriosidase activity in discriminating patients
according to GD severity. Involving several-fold more
participants than single primary studies, meta-analyses
can obtain more precise accuracy estimates [42].
Moreover, combining primary studies that enrolled
various populations of patients worldwide, meta-analyses
produce summary estimates with stronger generalizability
[42].
Compared to meta-analysis of aggregate data, our pro-
posed IPD approach has many potential advantages [19].
Indeed, the use of IPD enables implementation of con-
sistent inclusion and exclusion criteria across primary
studies, standardization of outcome definitions across
primary studies, investigation of heterogeneity in effect
size across subgroups of participants, and handling of
missing data. Overall, meta-analysis of IPD is considered
a more reliable approach than aggregate data meta-
analysis [19].
The potential limitations of our IPD meta-analysis
should be acknowledged. First, researcher reluctance for
sharing raw data is the main obstacle to performing IPD
meta-analysis [43]. The potential reasons explaining the
lack of data sharing include concerns about patient con-
fidentiality, lack of time, data ownership, the cost for de-
identifying and formatting the data, or the availability of
the data many years after the completion of the study
[43]. Principal investigators for several primary studies
have already expressed interest to collaborate in this
meta-analysis project and to provide IPD.
Second, the DerSimonian and Laird method may
underestimate the true between-study variance although
it is widely used in meta-analysis. An overview of pub-
lished simulations and empirical studies suggested that
the estimator proposed by Paule and Mandel may be a
better alternative to estimate between-study variance.
Yet a simulation study where all concurrent methods
would be compared is currently lacking [44].
Registration
The present protocol has been registered with the inter-
national Prospective Registry of Systematic Reviews
(PROSPERO 2015: CRD42015027243).
Additional files
Additional file 1: Appendix 1. Literature search strategy for MEDLINE via
PubMed. (DOCX 14 kb)
Additional file 2: Appendix 2. Primary study eligibility form. (DOCX 20 kb)
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